Emyria (ASX:EMD) has enrolled 50 patients and screened another 83 in its Phase 3 clinical trial to support the registration of its ultra-pure CBD capsule, EMD-RX5 as an over-the-counter (OTC) medicine.
The biotech company says EMD-RXD has a large potential patient market, saying mild anxiety and stress affect up to 15% of the adult population, with a higher prevalence in patients with chronic disease like chronic pain, which affects about 2.8 million adults in Australia.
Emyria says its trial program is on track to complete recruitment by July this year, with a clinical efficacy read-out anticipated in the subsequent month.
It also says while the TGA has allowed low-dose CBD of less than 150mg per day to be registered as an OTC medicine since December 2020, no CBD product has yet achieved that registration.